Amgen Income Statement | StatInvestor

Health Care & Life Sciences » Biotechnology | Amgen Inc.

Amgen Inc. | Income Statement

Fiscal year is January-December. All values USD Millions.

2013

2014

2015

2016

2017

2018

Sales/Revenue

18,672

20,035

21,336

22,683

22,784

23,768

Cost of Goods Sold (COGS) incl. D&A

3,346

4,219

4,227

4,162

4,069

4,101

Gross Income

15,326

15,816

17,109

18,521

18,715

19,667

SG&A Expense

9,261

8,968

8,981

8,960

8,432

9,069

EBIT

5,940

6,836

9,524

10,018

10,326

Unusual Expense

713

143

142

Non Operating Income/Expense

160

204

200

597

627

Interest Expense

1,021

1,070

1,046

1,269

1,303

1,392

Pretax Income

5,265

5,585

7,978

9,163

9,597

9,545

Income Tax

184

427

1,039

1,441

7,618

1,151

Consolidated Net Income

5,081

5,158

6,939

7,722

1,979

8,394

Net Income

5,081

5,158

6,939

7,722

1,979

8,394

Net Income After Extraordinaries

5,081

5,158

6,939

7,722

1,979

8,394

Net Income Available to Common

5,081

5,158

6,939

7,722

1,979

8,394

EPS (Basic)

6.64

6.70

9.06

10.24

2.69

12.62

Basic Shares Outstanding

753

759

758

748

731

661

EPS (Diluted)

6.64

6.70

9.06

10.24

2.69

12.62

Diluted Shares Outstanding

765

770

766

754

735

665

EBITDA

7,226

8,928

10,266

11,629

11,922

12,272

Other Operating Expense

125

265

272

Non-Operating Interest Income

248

706

877

1,192

371

1,246

Equity in Affiliates (Pretax)

About Amgen

View Profile

Address	One Amgen Center Drive Thousand Oaks California 91320 United States
Employees	-
Website	http://www.amgen.com
Updated	07/08/2019
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K.